2267 |
Dual Antiplatelet Therapy in the Era of 2nd Generation DES |
Hyeon-Cheol Gwon |
May. 09. 13 |
2266 |
Best Approach for CTO-PCI According to CTO Anatomy |
Etsuo Tsuchikane |
May. 09. 13 |
2265 |
Best Navigation of Retrograde Journey |
Etsuo Tsuchikane |
May. 09. 13 |
2264 |
Best Digging of Antegrade Route |
Yasushi Asakura |
May. 09. 13 |
2263 |
Need for Additional Emerging Targets? Ultimate Goal for Lipid Management |
Bum-Kee Hong |
May. 09. 13 |
2262 |
Unsettled Issues of Dyslipidemia in the Current Guideline |
Seung-Ho Hur |
May. 09. 13 |
2261 |
Calcified Vessel |
Fumitaka Hosaka |
May. 09. 13 |
2260 |
Bifurcation |
Junichi Yamaguchi |
May. 09. 13 |
2259 |
Is Potent Oral P2Y12 Inhibitor Enough to Prevent Thrombotic Events in High-risk PCI Patients? |
Young-Hoon Jeong |
May. 09. 13 |
2258 |
Upstream Use of GP IIb/IIIa Inhibitors: Indication, Efficacy and Safety |
Gian Battista Danzi |
May. 09. 13 |